Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Multiplace Series
Hard-Shell Multiplace·2-18+ person
Pressure3 ATA
$150,000 - $400,000+
●○○○Limited Evidence
Hyperbaric Therapy for Lyme Disease
An honest look at the evidence, what the Lyme community reports, and what pressure levels matter.
Key Takeaways
- 10–20% of Lyme patients develop chronic symptoms (PTLDS) lasting months or years after antibiotic treatment.
- In vitro studies show Borrelia burgdorferi is less viable under hyperbaric oxygen conditions.
- No large-scale RCTs have been conducted for HBOT and Lyme disease — evidence is limited.
- Most clinical use is at 2.0–2.4 ATA, beyond the range of home soft-shell chambers.
- HBOT is not FDA-approved for Lyme disease and is not covered by insurance.
- Approximately 476,000 Americans are diagnosed with Lyme disease annually.
What is Lyme Disease?
Lyme disease, caused by the spirochete Borrelia burgdorferi transmitted through tick bites, affects approximately 476,000 Americans annually. While most cases resolve with antibiotic treatment, 10–20% of patients develop post-treatment Lyme disease syndrome (PTLDS) — persistent fatigue, cognitive impairment, joint pain, and neurological symptoms lasting months or years after antibiotic therapy. The Lyme community has shown strong interest in HBOT as an adjunct therapy, and it is one of the most commonly sought alternative treatments among chronic Lyme patients.
How Hyperbaric Therapy Helps Lyme Disease
The rationale for HBOT in Lyme disease is based on several mechanisms. Borrelia burgdorferi is a microaerophilic organism — it thrives in low-oxygen environments. Elevated tissue oxygen from HBOT may create an inhospitable environment for persisting spirochetes. Additionally, HBOT reduces the neuroinflammation associated with Lyme neuroborreliosis, enhances immune function by improving white blood cell oxygen-dependent killing mechanisms, and may help repair damage to myelin sheaths and neural tissue caused by the infection. Many chronic Lyme patients also have impaired microcirculation, which HBOT directly addresses by increasing dissolved plasma oxygen.
Recommended Protocol
Pressure
2.0–2.4 ATA
Sessions
20–40 sessions
Duration
60–90 minutes per session
What Does the Evidence Say?
●○○○Limited Evidence
The evidence for HBOT in Lyme disease is limited but suggestive. A 1998 study by Fife et al. in a small case series showed improvement in symptoms after HBOT at 2.4 ATA. In vitro studies have demonstrated that Borrelia burgdorferi cultures exposed to hyperbaric oxygen show reduced viability. However, no large-scale randomized controlled trials have been conducted specifically for HBOT and Lyme disease. The evidence is largely anecdotal and based on clinical experience, patient reports, and the theoretical mechanism. The International Lyme and Associated Diseases Society (ILADS) acknowledges HBOT as a treatment option that some patients find beneficial, but it is not part of standard treatment guidelines.
Off-Label Use
Lyme Disease is not an FDA-approved indication for HBOT. Treatment is considered off-label and is typically not covered by insurance. Consult your physician before starting any HBOT protocol.
Recommended Chambers for Lyme Disease
Based on the protocol requirements — minimum 2 ATA, Clinical Grade tier. Sorted by clinical credibility score.
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 34
Hard-Shell Monoplace·1-person
Pressure3 ATA
$50,000 - $90,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 36
Hard-Shell Monoplace·1-person
Pressure3 ATA
$55,000 - $95,000
Clinical GradeFDA Cleared
For Maximum Comfort
Perry Baromedical
Sigma 40
Hard-Shell Monoplace·1-person
Pressure3 ATA
$65,000 - $110,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 40-II
Hard-Shell Multiplace·2-person
Pressure3 ATA
$100,000 - $160,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma Elite
Hard-Shell Monoplace·1-person
Pressure3 ATA
$80,000 - $130,000
Frequently Asked Questions
Does HBOT kill Lyme bacteria?
In vitro studies show that Borrelia burgdorferi cultures are less viable when exposed to hyperbaric oxygen. However, translating this to the human body is more complex — the spirochete can form biofilms and persist in low-oxygen tissue environments. HBOT may help create a less hospitable environment for the bacteria while supporting the immune system's ability to clear it, but it should not be considered a standalone cure.
Should I do HBOT alongside antibiotic treatment for Lyme?
Many Lyme-literate physicians use HBOT as an adjunct to antibiotic therapy, not a replacement. HBOT may potentiate certain antibiotics (oxygen enhances the bactericidal activity of some antibiotic classes) and may help antibiotics penetrate tissues with impaired circulation. Consult a Lyme-literate physician before combining treatments.
Will a 1.3 ATA chamber help with Lyme disease?
The limited evidence that exists uses 2.0+ ATA. The bacteriostatic effect on Borrelia and the immune-boosting mechanisms require meaningful oxygen elevation beyond what 1.3 ATA provides. For Lyme disease specifically, a clinical-grade chamber at 2.0+ ATA is recommended. Soft-shell chambers may provide some symptom relief (reduced inflammation, improved energy) but are unlikely to address the underlying infection.
Related Conditions
Sources & References
Last updated: March 2026. Data sourced from manufacturer specifications, FDA databases, and published clinical research.
Ready to compare chambers?
Use our filterable directory to find chambers that match your protocol requirements.